Chronic Heart Failure | Treatment Algorithms | Claims Data Analysis | US | 2017 November
First-line treatment of chronic heart failure (CHF) usually involves a beta blocker, an angiotensin-converting enzyme (ACE) inhibitor, and an oral diuretic. Second- or third-line treatments are often needed to better manage the disease. Physicians have numerous drug classes to choose from, most of which consist of drug options. The CHF market is heavily genericized, as such physician practice is minimally impacted by pricing pressures. The CHF Treatment Algorithm offers insight into prescribing patterns in this multi-layered treatment landscape where few branded agents jostle for patient share in a crowded sector. That said, small patient shares for such a prevalent indication can translate into significant commercial positions.
Related Market Assessment Reports
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
